179 related articles for article (PubMed ID: 11194214)
1. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
Moses RG; Gomis R; Frandsen KB; Schlienger JL; Dedov I
Diabetes Care; 2001 Jan; 24(1):11-5. PubMed ID: 11194214
[TBL] [Abstract][Full Text] [Related]
2. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
Damsbo P; Clauson P; Marbury TC; Windfeld K
Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
Van Gaal LF; Van Acker KL; De Leeuw IH
Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Owens DR
Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
[TBL] [Abstract][Full Text] [Related]
5. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
[TBL] [Abstract][Full Text] [Related]
6. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
Wolffenbuttel BH; Landgraf R
Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Raskin P; McGill J; Saad MF; Cappleman JM; Kaye W; Khutoryansky N; Hale PM;
Diabet Med; 2004 Apr; 21(4):329-35. PubMed ID: 15049934
[TBL] [Abstract][Full Text] [Related]
8. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.
Wang W; Bu R; Su Q; Liu J; Ning G
Expert Opin Pharmacother; 2011 Dec; 12(18):2791-9. PubMed ID: 21780853
[TBL] [Abstract][Full Text] [Related]
9. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
[TBL] [Abstract][Full Text] [Related]
10. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
[TBL] [Abstract][Full Text] [Related]
11. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
Moses R; Slobodniuk R; Boyages S; Colagiuri S; Kidson W; Carter J; Donnelly T; Moffitt P; Hopkins H
Diabetes Care; 1999 Jan; 22(1):119-24. PubMed ID: 10333912
[TBL] [Abstract][Full Text] [Related]
12. Repaglinide versus glyburide: a one-year comparison trial.
Marbury T; Huang WC; Strange P; Lebovitz H
Diabetes Res Clin Pract; 1999 Mar; 43(3):155-66. PubMed ID: 10369424
[TBL] [Abstract][Full Text] [Related]
13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
14. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes.
Landgraf R; Frank M; Bauer C; Dieken ML
Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S38-44. PubMed ID: 11063283
[TBL] [Abstract][Full Text] [Related]
15. The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.
Duran C; Tuncel E; Ersoy C; Ercan I; Selimoglu H; Kiyici S; Guclu M; Erturk E; Imamoglu S
J Endocrinol Invest; 2009 Jan; 32(1):69-73. PubMed ID: 19337019
[TBL] [Abstract][Full Text] [Related]
16. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
Moses R
Expert Opin Pharmacother; 2000 Dec; 1(7):1455-67. PubMed ID: 11249478
[TBL] [Abstract][Full Text] [Related]
17. Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial.
Gerstein HC; Garon J; Joyce C; Rolfe A; Walter CM
Diabet Med; 2004 Nov; 21(11):1200-3. PubMed ID: 15498086
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients.
Soegondo S; Subekti I; Luthariana L
Acta Med Indones; 2004; 36(3):142-7. PubMed ID: 15557683
[TBL] [Abstract][Full Text] [Related]
19. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
Owens DR; Luzio SD; Ismail I; Bayer T
Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
[TBL] [Abstract][Full Text] [Related]
20. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study.
Jovanovic L; Dailey G; Huang WC; Strange P; Goldstein BJ
J Clin Pharmacol; 2000 Jan; 40(1):49-57. PubMed ID: 10631622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
